Hyperfine, Inc.

Listed Company

HYPRCIK 0001833769NasdaqEmerging GrowthElectromedical & Electrotherapeutic ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$13.56M

Net Income

$-35.57M

Total Assets

$55.26M

Equity

$41.01M

Shares Out

Op. Cash Flow

$-27.95M

Business

Hyperfine, Inc. is a health technology company that develops and commercializes an AI-powered portable ultra-low-field magnetic resonance brain imaging system to increase access to MRI at the point of care. Its principal product is the Swoop® Portable MR Imaging® System, combining an ultra-low-field permanent magnet, deep-learning reconstruction and denoising, motion correction, a tablet user interface, cloud PACS and service/support programs. Commercial efforts target hospital critical care, emergency departments, neurology clinics and outpatient offices. The company sells directly in the U.S. and through third-party distributors in Canada, Europe, the U.K., Australia, New Zealand and select international markets.

Summary from filing dated 2025-03-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total sales	14	13	11	7	1
Total cost of sales	7	7	6	6	3
Gross profit	7	6	5	907,000	−1
Research and development	17	22	22	28	26
General and administrative	16	17	20	32	27
Sales and marketing	10	9	10	14	10
Total operating expenses	44	49	53	75	64
Loss from operations	−37	−43	−48	−74	−65
Interest income	1	2	4	761,000	18,000
Change in fair value of warrant liabilities	825,000	0	—	—	—
Other income (expense), net	−337,000	12,000	35,000	−51,000	−1,000
Loss before provision for income taxes	−36	−41	−44	−73	−65
Provision for income taxes	0	0	0	0	0
Net loss and comprehensive loss	−36	−41	−44	−44	−65
Net loss per common share attributable to common stockholders, basic	−0.43	−0.56	−0.62	−1.04	−17.57
Net loss per common share attributable to common stockholders, diluted	−0.43	−0.56	−0.62	−1.04	−17.57
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic	82	72	71	70	4
Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted	82	72	71	70	4

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	35	38	75	117	188
Restricted cash	957,000	28,000	621,000	771,000	3
Accounts receivable, less allowance of $1,372 and $651 in 2025 and 2024, respectively	5	6	3	2	553,000
Unbilled receivables	1	2	942,000	454,000	91,000
Inventory	7	6	7	5	4
Prepaid expenses and other current assets	1	2	2	3	1
Total current assets	51	54	89	129	197
Property and equipment, net	3	3	3	3	4
Other long term assets	2	2	2	2	1
Total assets	55	59	94	134	202
Accounts payable	4	2	1	678,000	2
Deferred grant funding	957,000	28,000	621,000	771,000	5
Deferred revenue	2	1	1	1	730,000
Accrued expenses and other current liabilities	5	6	5	6	8
Total current liabilities	12	9	9	9	16
Warrant liabilities	2	0	—	—	—
Long term deferred revenue	729,000	1	968,000	2	510,000
Other noncurrent liabilities	66,000	78,000	64,000	—	—
Total liabilities	14	10	10	10	16
COMMITMENTS AND CONTINGENCIES (NOTE 13)	—	—	—	—	—
Additional paid-in capital	371	343	338	333	323
Accumulated deficit	−330	−294	−254	−209	−136
Total stockholders' equity	41	49	84	124	186
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	55	59	94	134	202

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−36	−41	−44	−73	−65
Depreciation	1	1	1	1	—
Stock-based compensation expense	3	4	5	11	7
Write-off of equipment	121,000	215,000	224,000	—	—
Other	27,000	−11,000	25,000	91,000	85,000
Accounts receivable	702,000	−3	−1	−2	−379,000
Unbilled receivables	1	−1	−488,000	−363,000	−91,000
Inventory	−1	562,000	−2	−312,000	−3
Prepaid expenses and other current assets	436,000	−222,000	1	−2	−666,000
Prepaid inventory	0	693,000	−412,000	−281,000	—
Other long term assets	240,000	325,000	−220,000	−632,000	−1
Accounts payable	2	382,000	533,000	−2	1
Deferred grant funding	929,000	−593,000	−123,000	−2	1
Deferred revenue	−241,000	93,000	−483,000	2	1
Due to related parties	−11,000	0	61,000	−2	2
Accrued expenses and other current liabilities	332,000	−683,000	−742,000	−2	7
Operating lease liabilities, net	−8,000	−5,000	10,000	—	—
Net cash used in operating activities	−28	−39	−42	−72	−47
Purchases of property and equipment	−1	−383,000	−804,000	−585,000	−3
Net cash used in investing activities	−1	−383,000	−804,000	−585,000	−3
Proceeds from exercise of stock options	156,000	171,000	174,000	7,000	1
Proceeds from issuance of Class A common stock in connection with warrant exercises	337,000	0	—	—	—
Net cash provided by financing activities	28	1	174,000	7,000	177
Net decrease in cash and cash equivalents and restricted cash	−2	−38	−42	−73	127
Noncash acquisition of property and equipment	217,000	765,000	—	—	—
Unpaid purchase of property and equipment	31,000	0	3,000	—	—
Initial measurement of warrant liabilities	3	0	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro